Division of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC.
Department of Pathology and Pediatrics, The George Washington University Health Sciences, Washington, DC.
Pediatr Crit Care Med. 2022 Jan 1;23(13 Suppl 1 1S):e1-e13. doi: 10.1097/PCC.0000000000002854.
To present consensus statements and supporting literature for plasma and platelet product variables and related laboratory testing for transfusions in general critically ill children from the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.
Systematic review and consensus conference of international, multidisciplinary experts in platelet and plasma transfusion management of critically ill children.
Not applicable.
Critically ill pediatric patients at risk of bleeding and receiving plasma and/or platelet transfusions.
None.
A panel of 10 experts developed evidence-based and, when evidence was insufficient, expert-based statements for laboratory testing and blood product attributes for platelet and plasma transfusions. These statements were reviewed and ratified by the 29 Transfusion and Anemia EXpertise Initiative - Control/Avoidance of Bleeding experts. A systematic review was conducted using MEDLINE, EMBASE, and Cochrane Library databases, from inception to December 2020. Consensus was obtained using the Research and Development/University of California, Los Angeles Appropriateness Method. Results were summarized using the Grading of Recommendations Assessment, Development, and Evaluation method. We developed five expert consensus statements and two recommendations in answer to two questions: what laboratory tests and physiologic triggers should guide the decision to administer a platelet or plasma transfusion in critically ill children; and what product attributes are optimal to guide specific product selection?
The Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding program provides some guidance and expert consensus for the laboratory and blood product attributes used for decision-making for plasma and platelet transfusions in critically ill pediatric patients.
提出关于一般危重儿童输血中血浆和血小板制品变量以及相关实验室检测的共识声明和支持文献，该研究来自输血和贫血专业知识倡议-控制/避免出血。
对血小板和血浆输注管理的国际、多学科专家进行系统评价和共识会议，该研究针对危重症儿童。
不适用。
有出血风险且接受血浆和/或血小板输注的危重症儿科患者。
无。
一个由 10 名专家组成的小组为血小板和血浆输注的实验室检测和血液制品属性制定了基于证据的声明，在证据不足的情况下，制定了基于专家的声明。这些声明由 29 名输血和贫血专业知识倡议-控制/避免出血专家进行了审查和批准。从开始到 2020 年 12 月，使用 MEDLINE、EMBASE 和 Cochrane 图书馆数据库进行了系统评价。使用研究与开发/加利福尼亚大学洛杉矶分校适宜性方法获得共识。使用推荐评估、制定和评估方法总结结果。我们针对两个问题制定了五个专家共识声明和两个建议：在危重症儿童中决定输注血小板或血浆时，应使用哪些实验室检测和生理触发因素；以及哪些产品属性最适合指导特定产品选择？
输血和贫血专业知识倡议-控制/避免出血计划为实验室和血液制品属性提供了一些指导和专家共识，用于决策血浆和血小板输注在危重症儿科患者中的应用。
